FOLH1 and renal cell carcinoma: Subgroup analysis was based on the clinical indication (restaging of metastatic RCC vs. staging or evaluation of primary RCC), histopathology (all subtypes of RCC vs. studies that included solely ccRCC), and type of radiotracer (18F- vs. 68Ga-based PSMA radiotracers), when feasible.